IDH1 and acute myeloid leukemia: In patients with IDH1 mutated AML, ivosidenib is currently FDA approved as monotherapy for newly diagnosed and relapsed/refractory AML in patients with IDH1 mutations who are older than 75 years of age or unfit for intensive chemotherapy.